

Jeremy Levin: podcast appearances and interviews
Dr. · Ovid Therapeutics
About Jeremy Levin
Jeremy Levin, born in 1954, is a South African-born biopharmaceutical executive and medical doctor. He is affiliated with Ovid Therapeutics. Levin has been recognized as one of the most influential figures in the biopharmaceutical industry; in 2018, a publication highlighted his stature within the field. His contributions to the industry have earned him notable accolades, including the Lifetime Achievement Award at the 19th Annual Scrip Awards in London in 2023. Throughout his career, Levin has played a significant role in shaping advancements within biopharmaceutical research and development.
Summary based on Wikipedia, available under CC BY-SA.
Podcasts Jeremy Levin appeared on
Shows that have booked Jeremy Levin as a guest, ranked by appearance count.





Latest Jeremy Levin interviews
Every podcast episode Jeremy Levin has appeared on, newest first.


Dr. Jeremy Levin: Memorial Weekend Recap, Living Up to the American Dream, and Biotech Innovations

From US Army Intelligence to Private Sector Intelligence Advisor - Interview with Jeremy Levin (S02E05)

New Frontiers in Epilepsy and Seizure Treatments ft. Dr. Jeremy Levin and Meg Alexander, Ovid Therapeutics

IDEA Collider | Pharma Book Club | Dr Jeremy Levin
Frequently asked questions
What podcasts has Jeremy Levin been on?
Jeremy Levin has appeared on 5 podcasts across 5 episodes. Notable shows include Bay Area Innovators, The Voice of Reason with Andy Hooser, Intelligence Tradecraft - Sharpen your analytic edge.
What does Jeremy Levin do?
Jeremy Levin is Dr. at Ovid Therapeutics. Podcast appearances span topics tied to their work and expertise.
When was Jeremy Levin's most recent podcast appearance?
Jeremy Levin's most recent appearance was on "Why Americans Pay So Much for Drugs: A Pharma CEO Exposes the System". Bay Area Innovators, published Jun 5, 2026.
Which podcast has Jeremy Levin appeared on most often?
Bay Area Innovators. 1 appearance on record, most recently Jun 5, 2026.
